Bio-Techne Corporation logo TECH - Bio-Techne Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 12
HOLD 14
SELL 0
STRONG
SELL 0
| PRICE TARGET: $65.78 DETAILS
HIGH: $73.00
LOW: $50.00
MEDIAN: $73.00
CONSENSUS: $65.78
DOWNSIDE: 9.22%

Stock News

CMB.TECH SPECIAL GENERAL MEETING RESULTS

CMB.TECH SPECIAL GENERAL MEETING RESULTS

Antwerp, Oct. 08, 2026 (GLOBE NEWSWIRE) -- ANTWERP, Belgium, 8 October 2026, 15:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) announces that today the Special General Meeting of Shareholders (the “General Meeting”) has approved the proposed shareholder distribution of USD 0.64 per share, as conditionally announced on 27 August 2026 . All other resolutions proposed by CMB.TECH's Supervisory Board are also approved.

Oct 08, 2026 05:10 AM • globenewswire.com
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing MINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.

Oct 08, 2026 04:00 AM • prnewswire.com
INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE

INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE

(CSE: URAI / OTC: URAIF / FSE: 3QG0) [email protected] DomeCommand, the drone command-and-control platform the Company recently acquired, won first and third place in the two-day team integration category at the Singapore Defense Tech Hackathon 2026, in entries collaborating with partner teams. In the first-place entry, Team Echelon connected its acoustic localisation system and Team Aegis connected its interceptor drone to DomeCommand within the two-day event, demonstrating detection, localisation and coordinated interception in a competition setting.

Sep 29, 2026 08:56 AM • prnewswire.com
Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business

Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business

KEY HIGHLIGHTS Strategic Acquisition: Zhibao Technology Inc. (NASDAQ: ZBAO) ("Zhibao," "we," or the "Company") has entered into a definitive Merger and Acquisition Agreement dated September 28, 2026, to acquire 100% of the issued shares of NEXSYS TECH SDN. BHD. ("NEXSYS"), a newly incorporated Malaysian entity set to develop an AI computing infrastructure business.

Sep 28, 2026 04:00 AM • newsfilecorp.com
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.

Sep 23, 2026 05:20 AM • prnewswire.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA regions Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.

Sep 22, 2026 05:00 AM • prnewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Sep 09, 2026 07:43 AM • globenewswire.com
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensive Scope 3 emissions inventory completed MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.

Sep 01, 2026 02:30 AM • prnewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Aug 24, 2026 09:56 AM • globenewswire.com

Price Targets